Table 3 Bivariate regression analysis between patients with baseline dp-ucMGP <1000 and those >1000 pM
Baseline dp-ucMGP <1000 N = 5 | Baseline dp-ucMGP >1000 N = 45 | P-value | |
|---|---|---|---|
Age (years), median (IQR) | 55.0 (38.0; 64.0) | 73.0 (61.0; 80.0) | 0.02 |
Gender, male n (%) | 3 (60.0) | 27 (60.0) | 1.00 |
Dialysis vintage (months), median (IQR) | 36.0 (9.5; 152.0) | 47.0 (28.5; 108.5) | 0.73 |
Diabetes, n (%) | 2 (40.0) | 16 (35.6) | 1.00 |
Hypertension, n (%) | 3 (60.0) | 35 (77.8) | 0.58 |
Smoking, n (%) | 0 (0.0) | 8 (17.8) | 0.58 |
Calcification score, median (IQR) | 1.0 (0.5; 5.5) | 8.0 (2.0; 14.0) | 0.02 |
NCBB, n (%) | 2 (40.0) | 18 (40.0) | 1.00 |
Residual diuresis, n (%) | 0 (0.0) | 6 (13.3) | 1.00 |
Calcium dose (tablets of 600 mg), median (IQR) | 3.0 (1.5; 3.0) | 1.0 (1.0; 2.0) | 0.04 |
Alfacalcidol dose (μg), median (IQR) | 0.75 (0.25; 1.87) | 0.75 (0.00; 1.50) | 0.90 |
Serum phosphate (mg/dl), median (IQR) | 3.9 (3.6; 6.6) | 3.9 (3.0; 4.6) | 0.29 |
Serum calcium (mg/dl), median (IQR) | 9.3 (9.05; 9.65) | 9.1 (8.8; 9.2) | 0.09 |
PTH (pg/ml), median (IQR) | 127.0 (82.5; 297.0) | 196.0 (118.0; 270.0) | 0.29 |
LDL cholesterol (mg/dl), median (IQR) | 80.0 (72.0; 113.0) | 93.0 (77.0; 113.0) | 0.59 |
BMI (Kg/m2), median (IQR) | 30.2 (17.9; 34.3) | 25.8 (22.9; 27.8) | 0.69 |
URR, median (IQR) | 71.0 (65.0; 81.5) | 75.0 (72.0; 79.0) | 0.46 |
Albumin, median (IQR) | 40.0 (35.5; 44.5) | 39.0 (36.0; 41.0) | 0.44 |
CAD, n (%) | 1 (20.0) | 13 (28.9) | 1.00 |
Cinacalcet, n (%) | 0 (0.0) | 2 (4.4) | 1.00 |
Previous acenocoumadin, n (%) | 2 (40.0) | 4 (8.9) | 0.10 |
PTHX, n (%) | 0 (0.0) | 2 (4.4) | 1.00 |
Recent fracture, n (%) | 0 (0.0) | 3 (6.7) | 1.00 |